Le Lézard
Classified in: Health
Subject: SVY

PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities



NEW YORK, Oct. 6, 2017 /PRNewswire/ -- PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities

Summary

Read the full report: https://www.reportlinker.com/p05134501


Immuno-Oncology (IO) is uniquely positioned to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and other targeted treatments. In order to assist our clients with navigating the burgeoning amount information arising as a result of the rapidly growing field of IO clinical research, GlobalData is offering a comprehensive analysis of both pipeline and marketed active immunity IO therapies.

Scope
Key Topics Covered -
- Immune Checkpoint Modulators - Trends in Clinical Trial Development
- Competitive Assessment of Marketed PD-(L)1 Checkpoint Modulators
- Emergence of New Immune Checkpoint Targets
- Clinical and Commercial Opportunities for Highly Anticipated CAR Cell Therapies
- Cell Vaccines: Steady Development Stimulated by Prior IO Success
- Promising IO-IO Combinations Utilizing Oncolytic Viruses

Reasons to buy
- The PharmaFocus consists of a highly-visual slide deck that is intended to facilitate the dissemination of aggregated data and insights from analyses of over 800 IO products that are either marketed or in Phase I-III of clinical development.
- Types of graphical analyses include - Cumulative Plots, Aggregated Bubble Plots, Pie Charts, Matrix Analyses
- Unique, actionable insights applicable to IO drugs in five major categories: Immune Checkpoint Modulators, Cellular Immunotherapies, Oncolytic Viruses, Peptide Vaccines, and Bispecific T-Cell Engagers are provided in this report.
- Analysis of over 4000 clinical trials enrolling patients with 18 solid tumors and eight hematological cancers are included.

Read the full report: https://www.reportlinker.com/p05134501

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

https://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 01:47
Bayan Grocers Inc. is recalling Polly Ann brand frozen dessert bars from the marketplace because they contain milk which is not declared on the label. People with an allergy to milk should not consume the recalled products described below. The...

15 déc 2017
ESSA Pharma Inc. ("ESSA" or the "Company") announces an update to its previously announced pricing press release. The Company intends to issue up to 75,000,000 units of the Company ("Units") at a price of US$0.20 per Unit (the "Offering Price") for...

15 déc 2017
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Endologix, Inc. .   On August 2, 2016,...

15 déc 2017
The food recall warning issued on December 9, 2017 has been updated to include additional product information. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation. Imperial Caviar...

15 déc 2017
Valeant Pharmaceuticals International, Inc. ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the...

15 déc 2017
Recognizing that Centene Corporation's Washington subsidiary, Coordinated Care, has been in active discussions with the State of Washington Office of the Commissioner (OIC) for some time, today Coordinated Care finalized the terms of an agreement...




News published on 6 october 2017 at 11:12 and distributed by: